CNB Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

CNB Bank’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13	Closed	-$2K	–	422
2020 Q4	$2K	Buy	+13	New	+$1.54K	﹤0.01%	385

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

CNB Bank's RARE Position: Q1 2021 in Review

CNB Bank sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 13 shares — an estimated $2K sold.

CNB Bank first reported a position in RARE in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

CNB Bank reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
CNB Bank sold 13 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $2K.
CNB Bank first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 1 quarter.
CNB Bank's Ultragenyx Pharmaceutical position peaked at $2K in Q4 2020.
254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on CNB Bank's 13F filing for Q1 2021, filed 3 May 2021.